Journal for Immunotherapy of Cancer

Article	Citations
390 A global, molecular disease characterization initiative (MDCI) in oncology clinical trials	410
92 Single cell and spatial multiplex profiling of immune cell markers in FFPE tumor tissues using the novel RNAscope™ HiPlex v2 in situ hybridization assay	178
34 Selective infiltration of Antibody-Dependent Cellular Cytoxicity (ADCC) mediating immune cells in response to treatment in a human tumor histo-culture platform	167
Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions	140
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	139
EphA3 CAR T cells are effective against glioblastoma in preclinical models	132
62 Applying machine vision to empower preclinical development of cell engager and adoptive cell therapeutics in patient-derived organoid models of solid tumors	132
Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment	131
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial	126
Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient during immunotherapy	124
65 Identification of frequently presented non-mutated tumor-specific immunogens for the development of both off-the-shelf and personalized vaccines without need for tumor biopsy	123
214 SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma	123
Single-cell analysis reveals clonally expanded tumor-associated CD57+CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	120
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma	116
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial	112
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	111
Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate	109
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity	105
Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer	104
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression	103
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer	98
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines	96
90 Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers	96
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multi	96
Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment	91

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy	89
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma	88
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	87
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma	86
67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer	84
372 Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab	84
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers	84
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis	82
229 CX3CR1 in exhausted CD8 T cell states	82
Comments on roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation	81
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	81
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)	80
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	80
Liquid biopsies coming of age: biology, emerging technologies, and clinical translation- An introduction to the JITC expert opinion special review series on liquid biopsies	79
TIPE2deletion improves the therapeutic potential of adoptively transferred NK cells	79
High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells	78
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy	78
CARs are sharpening their weapons	78
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	78
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	78
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases	78
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial	77
Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy	76
Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity	76
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas	75
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine	75
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors	74
Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies	74
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study	74
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy	74
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma	73
Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy	72
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors	71
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients	71
Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma	71
GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies	70
The use of oncolytic virotherapy in the neoadjuvant setting	69
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	69
BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma	68
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment	68
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors	68
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma	68
Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy	67
Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy	66
Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment	66
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming	66
Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance	65
Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers	63
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC	61
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors	60

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	60
NLRC5germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors	59
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+TILs based onBRCA1/2mutation status in epithelial ovarian cancers	59
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden	59
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast c	59
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	59
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy	57
Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity	57
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treat	57
Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma	56
Intratumoral CXCL13+CD160+CD8+T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer	56
Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models	56
228 Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity	56
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study	55
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model	55
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro	54
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)	53
Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer	53
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity	53
Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).	53
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity	52
Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer	52
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way	52
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer	52
Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma	51
Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release	51
Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens	51
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study	51
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer	51
Better understanding of ICI-induced cholangitis for better management	51
Considerations for treatment duration in responders to immune checkpoint inhibitors	51
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy	51
Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al	51
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis	50
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab	50
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	50
Implication of99mTc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells	50
Mac Cheever (1944–2021): a tribute to a life of achievement and service	50
T-cell tolerant fraction as a predictor of immune-related adverse events	50
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	49
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL	49
Biomarkers for response to TIL therapy: a comprehensive review	49
Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer	48
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer	48
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report	48
Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab	47
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck	47
Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma	47
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+T cell infiltration and functional transition	45
Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia	45
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma	45
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy	44
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	44
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology	44
1α,25(OH)2D3reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells	44
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	44
CX-072 (pacmilimab), a Probody®PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study	44
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)	44
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy	44
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer	43
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma	43
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	43
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	43
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma	43
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth	43
Acknowledging and addressing real-world challenges to treating immune-related adverse events	43
Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study	43
Preclinical model for evaluating human TCRs against chimeric syngeneic tumors	42
Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma	42
CAR-T cell therapy in developing countries: how long should we wait?	42
Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC	42
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	42
Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity	42
Multimodal profiling of chordoma immunity reveals distinct immune contextures	41
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial	41
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemothera	41
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA	41
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity	40
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial	40
Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma	40

HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	40
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells	40
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade	40
Impact ofHelicobacter pyloriinfection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors	40
Hypoxia-inducible lentiviral gene expression in engineered human macrophages	40
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	40
277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial	40
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors	39
Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis	39
Perspectives on COVID-19 and cancer immunotherapy: a review series	39
Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by18F-BMS-986192 PET: pooled analysis of data from four solid tumor	39
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	39
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series	39
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy	39
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials	39
Neuroblastoma: an ongoing cold front for cancer immunotherapy	39
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers	39
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A+CD141+cDC1 and CD14+antigen-presenting cell recruitment	39
Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis	39
Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer	39
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report	38
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer	38
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma	38
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck	38
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer	38
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors	38
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models	38
Designed improvement to T-cell immunotherapy by multidimensional single cell profiling	38
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment	37
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia	37
Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression	37
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma	37
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy	37
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer	37
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?	37
System analysis based on the cancer–immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma	37
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target	37
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer	36
BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1	36
Commentary on oncolytic viruses: past, present, and future	36
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	36
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors	36
ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages	36
Helicobacter pyloriinfection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma	36
FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer	36
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer	36
Local anesthetics elicit immune-dependent anticancer effects	35
Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma	35
Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma	35
Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboringPOLEexonuclease domain mutation	35
Intratumoral administration of CD1c (BDCA-1)+and CD141 (BDCA-3)+myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory adva	35
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer	35
Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment	35
Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures	35
Location of CD39+T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer	34
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial	34
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer	34
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial	34
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures	34
Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma	34
Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway	34
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma	34
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	34
SPI1+CD68+macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies	34
Escherichia coliadhesin protein-conjugated thermal responsive hybrid nanoparticles for photothermal and immunotherapy against cancer and its metastasis	34
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study	33
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus	33
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	33
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer	33
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+pediatric solid	33
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma	33
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma	33
FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer	33
Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy	33
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers	33
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	33
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors	33
Autophagic flux restoration enhances the antitumor efficacy of tumor infiltrating lymphocytes	33
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy	33
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors	33
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma	33
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities	33
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	33
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity	32
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis	32
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity	32
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade	32
CD47/SIRPα axis: bridging innate and adaptive immunity	32
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)	32
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade	32
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors	32
Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment	32
Leveraging mitochondrial-programmed cell death dynamics to enhance prognostic accuracy and immunotherapy efficacy in lung adenocarcinoma	32
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment	32
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade	32